Two Sigma Investments
TVTX icon

Two Sigma Investments’s Travere Therapeutics TVTX Stock Holding History

Two Sigma Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.8M Buy
1,508,259
+351,452
+30% +$10.5M 0.04% 542
2025
Q4 		$44.2M Buy
1,156,807
+227,809
+25% +$7.41M 0.06% 389
2025
Q3 		$22.2M Buy
928,998
+10,285
+1% +$193K 0.03% 599
2025
Q2 		$13.6M Buy
918,713
+149,919
+20% +$2.48M 0.02% 686
2025
Q1 		$13.8M Buy
768,794
+75,778
+11% +$1.54M 0.03% 636
2024
Q4 		$12.1M Buy
693,016
+332,933
+92% +$5.89M 0.03% 668
2024
Q3 		$5.04M Buy
360,083
+45,903
+15% +$478K 0.01% 1081
2024
Q2 		$2.58M Sell
314,180
-225,904
-42% -$1.52M 0.01% 1381
2024
Q1 		$4.16M Buy
540,084
+171,415
+46% +$1.45M 0.01% 1072
2023
Q4 		$3.31M Buy
+368,669
New +$2.68M 0.01% 1210
2023
Q3 		– Sell
-441,267
Closed -$6.78M – 3227
2023
Q2 		$6.78M Sell
441,267
-112,446
-20% -$2.05M 0.02% 807
2023
Q1 		$12.5M Buy
553,713
+353,702
+177% +$7.52M 0.04% 509
2022
Q4 		$4.21M Buy
200,011
+90,845
+83% +$1.93M 0.01% 935
2022
Q3 		$2.69M Sell
109,166
-91,167
-46% -$2.36M 0.01% 1012
2022
Q2 		$4.85M Sell
200,333
-16,254
-8% -$409K 0.02% 788
2022
Q1 		$5.58M Buy
216,587
+119,187
+122% +$3.16M 0.02% 872
2021
Q4 		$3.02M Buy
+97,400
New +$2.74M 0.01% 1565
2021
Q2 		– Sell
-33,550
Closed -$838K – 4573
2021
Q1 		$838K Sell
33,550
-6,087
-15% -$168K ﹤0.01% 2476
2020
Q4 		$1.08M Buy
39,637
+27,837
+236% +$650K ﹤0.01% 1936
2020
Q3 		$218K Sell
11,800
-29,500
-71% -$573K ﹤0.01% 2774
2020
Q2 		$843K Sell
41,300
-37,390
-48% -$595K ﹤0.01% 1642
2020
Q1 		$1.15M Sell
78,690
-284,795
-78% -$4.28M 0.01% 1312
2019
Q4 		$5.16M Buy
363,485
+27,955
+8% +$357K 0.02% 930
2019
Q3 		$3.89M Buy
335,530
+79,757
+31% +$1.32M 0.01% 999
2019
Q2 		$5.14M Sell
255,773
-64,608
-20% -$1.28M 0.02% 879
2019
Q1 		$7.25M Buy
320,381
+19,508
+6% +$431K 0.02% 806
2018
Q4 		$6.81M Buy
300,873
+214,392
+248% +$5.33M 0.03% 668
2018
Q3 		$2.48M Sell
86,481
-47,092
-35% -$1.35M 0.01% 1332
2018
Q2 		$3.64M Buy
133,573
+16,060
+14% +$428K 0.01% 1205
2018
Q1 		$2.63M Buy
117,513
+77,134
+191% +$1.84M 0.01% 1336
2017
Q4 		$851K Sell
40,379
-93,624
-70% -$2.14M ﹤0.01% 2069
2017
Q3 		$3.33M Buy
+134,003
New +$2.95M 0.01% 1009
2017
Q2 		– Sell
-83,772
Closed -$1.55M – 3290
2017
Q1 		$1.55M Sell
83,772
-42,451
-34% -$830K 0.01% 1613
2016
Q4 		$2.39M Sell
126,223
-175,007
-58% -$3.58M 0.01% 1349
2016
Q3 		$6.74M Buy
301,230
+249,657
+484% +$4.75M 0.02% 733
2016
Q2 		$919K Sell
51,573
-51,644
-50% -$836K ﹤0.01% 1811
2016
Q1 		$1.41M Sell
103,217
-5,739
-5% -$87.1K 0.01% 1398
2015
Q4 		$2.1M Sell
108,956
-178,022
-62% -$3.56M 0.01% 1061
2015
Q3 		$5.81M Buy
286,978
+271,614
+1,768% +$8.05M 0.03% 486
2015
Q2 		$509K Buy
+15,364
New +$421K ﹤0.01% 2112

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments's TVTX Position: Q1 2026 in Review

Two Sigma Investments increased its Travere Therapeutics (TVTX) stake by 30% in Q1 2026, buying an estimated $10.5M and bringing the position to 1,508,259 shares worth $44.8M. The position accounts for 0.04% of the portfolio, ranked #542.

Two Sigma Investments first reported a position in TVTX in Q2 2015 and has held it in 40 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Two Sigma Investments held 1,508,259 shares of Travere Therapeutics worth $44.8M as of Q1 2026.
  • Two Sigma Investments bought 351,452 Travere Therapeutics shares in Q1 2026, an estimated $10.5M.
  • Travere Therapeutics made up 0.04% of Two Sigma Investments's portfolio in Q1 2026, its #542 holding.
  • Two Sigma Investments first reported a position in Travere Therapeutics in Q2 2015 and has held it in 40 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.